Papp L Roy & Associates lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,780 shares of the medical research company’s stock after selling 498 shares during the period. Papp L Roy & Associates’ holdings in Amgen were worth $1,637,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Janus Henderson Group PLC raised its holdings in Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares in the last quarter. FMR LLC raised its holdings in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Amgen by 40.9% during the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after acquiring an additional 986,700 shares in the last quarter. BlackRock Inc. raised its holdings in Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares in the last quarter. Institutional investors and hedge funds own 78.46% of the company’s stock.
Several analysts recently issued reports on AMGN shares. Vetr lowered Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price on the stock. in a report on Wednesday, January 3rd. Mizuho reiterated a “buy” rating and set a $198.00 target price (up previously from $183.00) on shares of Amgen in a report on Thursday, September 28th. Piper Jaffray Companies reiterated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. BMO Capital Markets reiterated a “hold” rating and set a $198.00 target price on shares of Amgen in a report on Friday, October 20th. Finally, Jefferies Group restated a “buy” rating and issued a $200.00 price objective on shares of Amgen in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have assigned a buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus price target of $190.15.
Amgen, Inc. (NASDAQ AMGN) opened at $185.04 on Friday. Amgen, Inc. has a 12-month low of $150.38 and a 12-month high of $191.10. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. The company has a market capitalization of $134,322.56, a P/E ratio of 14.71, a PEG ratio of 2.70 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the prior year, the business earned $3.02 earnings per share. The firm’s revenue for the quarter was down .7% on a year-over-year basis. sell-side analysts expect that Amgen, Inc. will post 12.71 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 annualized dividend and a dividend yield of 2.85%. Amgen’s dividend payout ratio is presently 41.63%.
Amgen announced that its Board of Directors has initiated a share buyback program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
What are top analysts saying about Amgen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen and related companies.